BFW - You might be correct with the statement copied below. I also feel this doesn't totally say nothing could be revealed for CKD or cognitive sub-studies before Nov. 16th. DM might have been referring until then to get clarity on the CVD studies since that was where the primary endpoint was measured. That area was the big fail and we need clarity there especially between Rosuvastatin and Atorvastatin. Even if CKD or cognitive sub-studies show promise, those need a lot of proving up which takes time. With better clarity on CVD in November showing a successful trial, we might be back on track much sooner. That could have influenced his statement of wait until then due to the importance of CVD as the primary endpoint of the trial.

"In the conference call, Don indicated that we should wait until November 16th to see the data....which would be enlightening. One could extrapolate that positive secondary endpoints would not be released prior to that date. Otherwise, why should we have to wait until November 16 minimum?"